On May 21, Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Abstract #5559 is entitled, “Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy.” The data will be presented during the Gynecologic Cancer General Poster Session on Saturday May 31, 2014 from 8:00 am to 11:45 am CDT in S Hall A2. Galena Biopharma Inc (NASDAQ:GALE) weekly performance is 14.90%. On last trading day company shares ended up $2.39. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is 2.01%.
On May 27, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that the company is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time) at the Grand Hyatt in New York, New York. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended the day on $6.26. Gross Margin is 93.70% and its return on assets is -8.10%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is -7.53%.
On May 28, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will provide an overview of the Company’s business at three upcoming investor conference: The Jefferies Global Healthcare Conference in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will present on Wednesday, June 4 at 2:30 p.m. (ET). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 0.16% in last trading session and was closed at $6.38, while trading in range of $6.36 – $6.49. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -6.45%.
MannKind Corporation (NASDAQ:MNKD) will present at upcoming conferences. Jefferies 2014 Global Healthcare Conference on June 2, 2014 at 2:30 pm (ET) in New York, New York; Goldman Sachs 35th Annual Global Healthcare Conference on June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $8.55. Company weekly volatility is calculated as 4.93% and price to cash ratio as 92.81. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 9.48%.
On May 28, Bayer AG (ADR) (OTCMKTS:BAYRY) said Wednesday that Andreas Fibig, President of Bayer Healthcare Pharmaceuticals, will leave the company on Sept. 1. A successor for Mr. Fibig, who is also a member of the Bayer Healthcare Executive Committee, will be named in the coming days, Bayer said in a statement. Mr. Fibig, who will become chief executive of International Flavors and Fragrances Inc., has held the post since September 2008. Bayer AG (ADR) (OTCMKTS:BAYRY) On last trading day company shares ended up $143.56.
Leave a Reply